Clinical trials: CMV Disease, open to volunteers
Epstein-Barr Virus Infections, Cytomegalovirus Infections
R-MVST Cells for Treatment of Viral Infections
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV)…
- Conditions
- Epstein-Barr Virus Infections, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
- Trial name
- NCT05183490
- Testing
- Rapidly generated virus specific T (R-MVST) cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Columbia University
Cytomegalovirus (CMV) Infection
ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse
The goal of this clinical trial is to learn if valganciclovir works to treat cytomegalovirus (CMV) infection in people with advanced HIV disease.
- Trial name
- NIRVANA (NCT07379203)
- Testing
- Valganciclovir
- Volunteers
- 130 people
- Sponsor
- Wits Health Consortium (Pty) Ltd
AdV Infection, EBV Infection
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality.
- Conditions
- AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
- Trial name
- TRACE (NCT04832607)
- Testing
- Multivirus (CMV, EBV, AdV)-specific T cells
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Tobias Feuchtinger
Congenital CMV Infection, Sensorineural Hearing Loss
Long-Term Outcomes of Children With Congenital CMV in New York State
PROACTIVE NYS is a long-term follow-up study of all infants who test positive for congenital Cytomegalovirus infection (CMV) throughout New York State on the Newborn Screen.
- Trial name
- PROACTIVE NYS (NCT06226558)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Stony Brook University
High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma
Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma
This phase I trial studies the safety and feasibility of cytomegalovirus (CMV) specific CD19-chimeric antigen receptor (CAR) T cells in combination with the CMV-modified vaccinia Ankara (MVA) triplex vaccine following…
- Conditions
- High Grade B-Cell Non-Hodgkin's Lymphoma, Intermediate Grade B-Cell Non-Hodgkin's Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT05801913
- Testing
- Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Adenovirus, Cytomegalovirus Infections
Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity
The primary purpose of this phase I/II study is to evaluate whether partially matched, ≥2/6 HLA-matched, viral specific T cells have efficacy against adenovirus, CMV, and EBV, in subjects who have previously received any type of…
- Conditions
- Adenovirus, Cytomegalovirus Infections, Epstein-Barr Virus Infections
- Trial name
- NCT06909110
- Testing
- Adenovirus Specific T- Lymphocytes, Cytomegalovirus Specific T-Lymphocytes, Epstein-Barr Virus Specific T-Lymphocytes
- Where
- 3 sites in United States
- Volunteers
- 25 people
- Sponsor
- Jessie L. Alexander
Viral Infection
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
The purpose of this study is to use VSTs (virus-specific T cells) from a donor that is a partial HLA (human leukocyte antigen) match with the patient to treat viral infections after an allogeneic hematopoietic stem cell…
- Trial name
- TETRAVI (NCT04013802)
- Testing
- HLA-matched VSTs
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Baylor College of Medicine
Sanfilippo Syndrome (MPS III)
Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIB
The goal of this clinical trial is to learn if one infusion of rAAV9-CMV-hNAGLUop can treat patients with Sanfilippo syndrome (MPS III) 6 months or older.
- Trial name
- NCT07818759
- Testing
- rAAV9-CMV-hNAGLUop
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NeuroGT
CMV, Lung Transplant Recipient
Combination Letermovir and Standard of Care Antiviral for Enhanced Antiviral Response in Cytomegalovirus Infection in Lung Transplant Recipients
The primary objective of the CLEAR-CMV trial is to evaluate the efficacy of letermovir therapy plus standard of care (SOC) antiviral compared to SOC plus placebo in achieving clearance of CMV viremia by week 3 in lung transplant…
- Trial name
- CLEAR-CMV (NCT07235683)
- Testing
- Letermovir, Valganciclovir/Ganciclovir
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Cytomegalovirus Infection
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
The purpose of this study is to evaluate the efficacy and the tolerance of letermovir as part of dual antiviral therapy (in association with valganciclovir) in renal transplant recipients with CMV DNAemia, requiring…
- Trial name
- LUCY-1 (NCT06334497)
- Testing
- Letermovir, Valganciclovir
- Where
- 5 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation
HCMV-miRNA Monitoring After Allogeneic Hematopoietic Stem Cell Transplantation Using PSTM-qPCR
Human cytomegalovirus (HCMV) infection is one of the most common and serious complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Virus Reactivation, Graft vs Host Disease
- Trial name
- HSCT-HCMV01 (NCT07210242)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Ting YANG
Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT)
CMV-CMI in csCMVi After HSCT
Cytomegalovirus (CMV) reactivation is a common and serious complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and the reconstitution of CMV-specific cell-mediated immunity (CMV-CMI) plays a key…
- Conditions
- Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation (HSCT), Immune Reconstitution
- Trial name
- NCT07688759
- Testing
- Anti-Cytomegalovirus Therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Epstein-Barr Virus, Cytomegalovirus Infections
R-MVST Cells for Treatment of Viral Infections in Children and Young Adults
The primary objective is to determine the safety and feasibility of administering R-MVST cells to patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV)…
- Conditions
- Epstein-Barr Virus, Cytomegalovirus Infections, Adenovirus, BK Virus Infection
- Trial name
- NCT06926894
- Testing
- Rapidly generated virus specific T (R-MVST) cells
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Monica Bhatia
Congenital Cytomegalovirus, Cytomegalovirus Infections
Protein Biomarkers and Host RNA Expression Profiles in Congenital Cytomegalovirus Infection
This study seeks to identify and test host protein biomarkers and RNA expression profiles in dried blood spot samples as novel diagnostic markers of congenital cytomegalovirus sequelae and to improve the understanding of the…
- Conditions
- Congenital Cytomegalovirus, Cytomegalovirus Infections, Neonatal Infection, Sensorineural Hearing Loss
- Trial name
- NCT07635368
- Where
- 2 sites in Denmark
- Volunteers
- 630 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Cytomegalovirus Infections
Ganciclovir Resistant/Refractory Cytomegalovirus Infection in SOT Recipients and HSCT Patients
The ReCySOHT study is a multicenter, retrospective, observational case-control study on the risk factors for developing a ganciclovir-resistant/refractory (GCV-RR) cytomegalovirus infection in patients receiving solid organ…
- Trial name
- ReCySOHT (NCT05234723)
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 100 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cytomegalovirus, Organ Transplant
Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)
This study is being done to find out if administering CytoGam® after the end of standardly prescribed preventive antiviral treatment can help transplant recipients with a high risk for developing late CMV disease after a liver…
- Conditions
- Cytomegalovirus, Organ Transplant, Kidney Transplant; Complications, Liver Transplant Complications
- Trial name
- SHIELD (NCT06958796)
- Testing
- Cytomegalovirus Immune Globulin Intravenous (Human) monthly for three months
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Camille N. Kotton, MD
Acute Lymphoblastic Leukemia
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
This early phase I trial tests the safety and side effects of allogeneic CMV-specific CD19-CAR T cells plus CMV-MVA vaccine and how well it works in treating patients with high-risk acute lymphoblastic leukemia after a matched…
- Trial name
- NCT06735690
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
CMV Infection
HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial
Cytomegalovirus (CMV) remains a significant cause of morbidity and mortality following organ transplantation. Cell-mediated immunity plays a crucial role in controlling CMV replication after transplantation.
- Trial name
- HORUS-COPE (NCT07570433)
- Testing
- 50% reduction in the dose of MPA, Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus, standard antiviral therapy along with maintenance of their initial immunosuppressive therapy.
- Where
- 4 sites in France, Spain and 1 more
- Volunteers
- 100 people
- Sponsor
- Oriol Manuel
Cytomegalovirus Infections, CMV
Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT
After allogeneic hematopoietic stem cell transplantation (allo-HSCT), recipients are immunocompromised and at increased risk of complications, including cytomegalovirus (CMV) infection.
- Trial name
- NCT06812598
- Testing
- Letermovir (0-24w）, Letermovir (0-14w）
- Where
- China
- Volunteers
- 330 people
- Sponsor
- The First Affiliated Hospital of Soochow University